Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study

Malene Martini Clausen, Anders E Hansen, Per Munck Af Rosenschold, Andreas Kjaer, Annemarie Thuri Kristensen, Fintan McEvoy, Svend A Engelholm

15 Citationer (Scopus)

Abstract

Glycolytic activity and hypoxia are associated with poor prognosis and radiation resistance. Including both the tumor uptake of 2-deoxy-2-[18 F]-fluorodeoxyglucose (FDG) and the proposed hypoxia tracer copper(II)diacetyl-bis(N4)-methylsemithio-carbazone (Cu-ATSM) in targeted therapy planning may therefore lead to improved tumor control. In this study we analyzed the overlap between sub-volumes of FDG and hypoxia assessed by the uptake of 64Cu-ATSM in canine solid tumors, and evaluated the possibilities for dose redistribution within the gross tumor volume (GTV).
OriginalsprogEngelsk
TidsskriftRadiation Oncology
Vol/bind8
Sider (fra-til)262
ISSN1748-717X
DOI
StatusUdgivet - 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study'. Sammen danner de et unikt fingeraftryk.

Citationsformater